
A Monday session at the 2022 American Academy of Dermatology Annual Meeting discussed strategies for risk stratification and therapeutic management of nonmelanoma skin cancers.


A Monday session at the 2022 American Academy of Dermatology Annual Meeting discussed strategies for risk stratification and therapeutic management of nonmelanoma skin cancers.

The FDA approved a drug to treat a rare form of childhood epilepsy; uninsured Americans will no longer have access to free COVID-19 tests; a conservation group is suing the Environmental Protection Agency (EPA) over failure to protect rivers from pollution.

It’s important that patients understand the likely outcomes, problems that can occur along the way, and the risks of a treatment or procedure, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

A new study has found that internalized skin bias has a role in diminishing HRQOL and negatively affects mental health among these patients.

Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.

Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.

Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead, Rheumatology Therapeutic Area at Janssen, speaks on nontherapeutic approaches to manage symptom burden of psoriatic arthritis.

Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.

Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.

The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.

An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.

The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.

There is evidence that people with HIV may have increased risk of cardiovascular disease and researchers are still trying to understand why, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.

Angela Storseth-Cooper, associate director, Government Relations & Public Policy, The US Oncology Network, discusses state-level legislation that community oncology practices can leverage to address issues involving pharmacy benefit managers and the vertical integration of health plans and specialty pharmacies.

Lower risk of discontinuation was found with ustekinumab vs the biologics adalimumab, secukinumab, and ixekizumab, in the treatment of patients with moderate to severe psoriasis.

The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.

The World Health Organization warns of long-term health impacts from the Ukraine crisis; states sign legislation aimed at curbing abortion access; over 14 million Americans signed up for health insurance through the Affordable Care Act.

This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.

Coverage of COVID-19 tests and treatment bills halted for uninsured; Moderna low-dose vaccine in children under 6 years of age shows promise in early clinical trial findings; Pfizer recalls blood pressure medications due to potential carcinogen.

Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.

A study found that dementia was associated with patient mortality and length of stay when patients with chronic obstructive pulmonary disease (COPD) were admitted to a hospital.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
